Format

Send to

Choose Destination
Lung Cancer. 2017 Apr;106:50-57. doi: 10.1016/j.lungcan.2017.02.007. Epub 2017 Feb 6.

SBRT for oligoprogressive oncogene addicted NSCLC.

Author information

1
Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, CH 8091 Zurich, Switzerland. Electronic address: Lucas.Basler@usz.ch.
2
Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, CH 8091 Zurich, Switzerland.

Abstract

Lung cancer is one of the leading causes of cancer death in men and women and treatment outcome continues to lag behind other common cancer types. A subset of lung adenocarcinoma patients exhibit a somatic mutation in EGFR or an ALK rearrangement. In these patients, targeted TKI therapy results in higher response rates, improved PFS and reduced side effects compared with platinum-based chemotherapy. Despite initial activity of the TKIs, ultimately all patients present with disease progression after about a year on TKI therapy due to resistance development. About 15-47% of patients present with limited oligoprogressive disease (OPD): such patients show only a limited number of metastases with progression in radiological imaging. Radical local treatment to all oligoprogressive lesions is thought to eradicate the de-differentiated clones and restore overall sensitivity of the metastatic disease. Retrospective studies suggest that aggressive local treatment using stereotactic body radiotherapy (SBRT), surgery or others can be used to eradicate TKI-resistant subpopulations enabling prolonged TKI treatment "beyond progression", which may lead to increased PFS and overall survival. This review focuses on the biological background of resistance development, systemic and local treatment options with a focus on SBRT, as well as challenges in defining the state of OPD and current clinical studies in oligoprogressive oncogene addicted NSCLC.

KEYWORDS:

EGFR mutation; Oligoprogressive disease (OPD); Oncogene addicted lung cancer; Resistance to targeted therapy; Stereotactic body radiotherapy (SBRT); Tyrosine kinase inhibitors

PMID:
28285694
DOI:
10.1016/j.lungcan.2017.02.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center